Pictured above: Liam Talbot and Charli Robinson present Icon Cancer Foundation with transformative $2.5 million donation to cancer research. (Left-to-right: Dr Jonathan Ramsay, Ross Koscharsky, Leanne Hardyman, Liam Talbot, Charli Robinson).
Philanthropic investment is helping expand access to one of the most promising frontiers in cancer treatment, with Icon’s growing cellular therapy program bringing new hope to patients across Australia.
Supported by Icon Cancer Foundation (ICF) and its donor community, the program is enabling greater access to advanced therapies such as CAR T-cell treatment, particularly for people with blood cancers where options can be limited.
Currently, CAR T-cell therapy is only available in the private health system through participation in clinical trials, making access to these studies critical for eligible patients.
Group Executive Research Manager Sophie Mepham PhD says cellular therapy is transforming what is possible in cancer care.
“These treatments are highly specialised and complex to deliver, but they offer new hope where traditional options may be limited,” Dr Mepham said.
“Building the capability to offer them more broadly is a significant step forward for patients.”
Icon has recently activated its first CAR T-cell therapy clinical trial – the ALPHA3 study – helping expand access to advanced treatment options. While the trial itself is supported by a pharmaceutical sponsor, the ability for Icon to coordinate and deliver it has been made possible through sustained investment in research capability and infrastructure.
“Philanthropic investment has played a critical role in enabling this progress,” Dr Mepham said. “It allows us to build the foundations – people, systems and expertise – that make it possible to bring global clinical trials to Australian patients.”
In recent years, a combination of major donations and community fundraising has supported every aspect of the program, from research infrastructure through to specialist research roles that ensure these therapies can be delivered safely and effectively.
A $2.5 million donation from the Talbot Foundation is funding critical research infrastructure, supporting the delivery of advanced treatments and expanding access to clinical trials, particularly in cellular and novel therapies.
Philanthropic support has also enabled dedicated research leadership, including the role of Dr Karthik Nath, Icon’s Deputy Director of Cellular Therapy. Since joining Icon in 2024, Dr Nath’s international experience has helped attract global clinical trials and strengthen research capability in Australia.
Alongside this, community fundraising is playing a direct role in improving the patient experience.
Pictured: Liam Talbot and Charli Robinson present Icon Cancer Foundation with a $2.5 million donation on behalf of The Talbot Foundation, to support life-changing cancer research and clinical trials. (Left-to-right: Associate Professor Jim Coward, Dr Ian Irving, Associate Professor James Morton AM, Charli Robinson, Liam Talbot, Dr Karthik Nath).
“Philanthropic investment has played a critical role in enabling this progress. It allows us to build the foundations – people, systems and expertise – that make it possible to bring global clinical trials to Australian patients.”
Icon Group Executive Research Manager
A $265,000 fundraising effort led by the O’Brien family, together with ongoing support from Ray White New Farm, has funded a specialised Cellular Therapy Coordinator. This nursing role supports patients through complex treatments and clinical trials, ensuring continuity of care.
Community and Partnerships Manager Leanne Hardyman says the impact of donor support can be seen across the entire patient journey.
“For donors, it’s incredibly meaningful to see how their support translates into real outcomes for patients,” Ms Hardyman said.
“Whether it’s funding a clinical trial, a specialist role or critical infrastructure, every contribution is helping bring new treatment options closer to people who need them.”
Pictured: Josephine O’Brien presenting at the Ray White New Farm Long Lunch.
While cellular therapy is a key focus, it forms part of a broader research effort supported by ICF across multiple cancer types and novel new therapies. Continued investment will be essential to expand clinical trials, bring more world-first treatments to Australia and reach more patients, sooner.
“Research doesn’t happen in isolation,” Ms Hardyman said. “It’s made possible by a community of supporters who are committed to improving outcomes for people facing cancer, now and into the future.”
“Whether it’s funding a clinical trial, a specialist research role or critical research infrastructure, every contribution is helping bring new treatment options closer to people who need them.”
Icon Cancer Foundation Community and Partnerships Manager
Support Icon Cancer Foundation and give to cancer research.
ICF’s annual appeal will build on this momentum, supporting research, clinical trials and patient care initiatives that accelerate access to new treatments.
How people choose to get involved, whether by donating, partnering or sharing this work, they are helping bring new treatment options closer to patients.
Together, this collective effort is driving progress in cancer research and improving outcomes for people facing cancer today and into the future.